沙利度胺联合卡培他滨节拍化疗治疗转移性乳腺癌临床疗效及安全性分析.docVIP

沙利度胺联合卡培他滨节拍化疗治疗转移性乳腺癌临床疗效及安全性分析 　　[摘要] 目的 分析沙利度胺联合卡培他滨节拍化疗治疗转移性乳腺癌的临床疗效及安全性。方法 研究对象方便选取该院2012年6月―2015年5月收治的76例转移性乳腺癌患者，采用电脑随机的方式分为研究组与参比组各38例。研究组患者接受沙利度胺联合卡培他滨节拍化疗治疗；参比组患者行常规化疗。对两组患者的疗效、不良反应情况进行观察对比。 结果 研究组患者的治疗有效率为63.16%（24/38），对比参比组患者的68.42%（26/38），差异无统计学意义（P0.05）；研究组患者骨髓抑制反??发生率为39.47%、手足综合征10.53%、消化道不良反应18.42%，参比组患者为71.05%、26.32%和42.86%，差异有统计学意义（P0.05）。结论 沙利度胺联合卡培他滨节拍化疗治疗转移性乳腺癌的疗效与常规化疗接近，但是不良反应发生率明显更低。 　　[关键词] 利度胺；卡培他滨；节拍化疗；转移性乳腺癌；安全性 　　[中图分类号] R737.9 [文献标识码] A [文章编号] 1674-0742（2017）01（c）-0142-03 　　Analysis of Clinical Curative Effect and Safety of Thalidomide and Capecitabine in the Metronomic Chemotherapy of Metastatic Breast Cancer 　　ZHANG Ying 　　Department of Medical Oncology， Inner Mongolia Autonomous Region Peoples Hospital，Hohhot，Inner Monglia， 010010 China 　　[Abstract] Objective To analyze the clinical curative effect and safety of thalidomide and capecitabine in the chemotherapy of metastatic breast cancer. Methods 76 cases of patients with metastatic breast cancer admitted and treated in our hospital from June 2012 to May 2015 were convenient selected and randomly divided into two groups with 38 cases in each， the research group were treated with thalidomide and capecitabine， while the control group were treated with routine method， and the curative effect and adverse reactions of the two groups were observed and compared. Results The difference in the treatment effective rate between the research group and the control group had no statistical significance[63.16%（24/38） vs 68.42%（26/38）]，（P0.05）； the differences in the incidence rate of bone marrow suppression reaction， hand-foot syndrome and gastrointestinal side effect between the research group and the control group had statistical significance（39.47%， 10.53%， 18.42% vs 71.05%， 26.32%， 42.86%）（P0.05）. Conclusion The curative effect of thalidomide and capecitabine in the chemotherapy of metastatic breast cancer is similar to that of the routine chemotherapy， but the incidence rate of adverse